Aviva PLC Buys 414,008 Shares of CVS Health Co. (NYSE:CVS)

Aviva PLC raised its stake in CVS Health Co. (NYSE:CVS) by 154.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 681,209 shares of the pharmacy operator’s stock after acquiring an additional 414,008 shares during the period. Aviva PLC’s holdings in CVS Health were worth $30,579,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. EagleClaw Capital Managment LLC raised its stake in CVS Health by 3.4% in the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock worth $275,000 after buying an additional 200 shares in the last quarter. Manchester Capital Management LLC grew its stake in CVS Health by 4.8% in the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock valued at $200,000 after purchasing an additional 204 shares during the last quarter. Angeles Investment Advisors LLC lifted its position in shares of CVS Health by 3.7% during the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock valued at $256,000 after buying an additional 204 shares during the last quarter. Rogco LP boosted its holdings in shares of CVS Health by 3.2% in the 4th quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock valued at $303,000 after buying an additional 210 shares in the last quarter. Finally, Cozad Asset Management Inc. grew its position in shares of CVS Health by 3.7% in the 4th quarter. Cozad Asset Management Inc. now owns 6,532 shares of the pharmacy operator’s stock worth $293,000 after buying an additional 233 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 5.9 %

CVS stock opened at $63.54 on Monday. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $74.85. The company’s 50-day simple moving average is $63.47 and its 200-day simple moving average is $58.01. The firm has a market cap of $80.11 billion, a P/E ratio of 17.36, a PEG ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, equities analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s dividend payout ratio is presently 72.68%.

Wall Street Analysts Forecast Growth

CVS has been the subject of several recent analyst reports. Barclays raised their target price on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. UBS Group dropped their target price on CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 11th. Argus set a $77.00 price target on CVS Health in a research note on Tuesday, February 18th. StockNews.com raised CVS Health from a “sell” rating to a “hold” rating in a report on Thursday, February 13th. Finally, Truist Financial upped their price objective on shares of CVS Health from $60.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and a consensus price target of $70.39.

Insider Buying and Selling

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. The trade was a 320.65 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is owned by company insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.